Article

Phase II trial to study DME

The Juvenile Diabetes Research Foundation (JDRF) is enrolling patients in a study to test the long-term safety and effectiveness of intraocular injections of ranibizumab (Lucentis, Genentech) in patients with diabetic macular edema (DME)

New York-The Juvenile Diabetes Research Foundation (JDRF) is enrolling patients in a study to test the long-term safety and effectiveness of intraocular injections of ranibizumab (Lucentis, Genentech) in patients with diabetic macular edema (DME)

The Ranibizumab for Edema of the Macula in Diabetes phase II (READ 2) study, supported by Genentech and JDRF, builds on the results of the foundation's phase I trial. In that trial, ranibizumab was shown to improve visual acuity in patients with DME, with no adverse events related to the drug. Median and mean visual acuity improved by 11 and 12.3 letters respectively at 7 months.

READ 2 will look at additional dosing and safety information, as well as combination therapy of ranibizumab and laser photocoagulation.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
© 2025 MJH Life Sciences

All rights reserved.